Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576717 · ClinicalTrials.gov registry record · Phase 3
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
A Phase 3 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,494
- Enrollment target
NCT02576717 is a Phase 3 study that has completed, run by Celgene. The registered enrollment target is 2,494 participants.
The verdict
NCT02576717, a Phase 3 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,494 participants
- Enrollment target
Study Summary
The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
Interventions
- DRUG RPC1063
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,494 participants |
| Start Date | 2015-10-16 |
| Est. Completion | 2023-01-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02576717
The ClinicalTrials.gov registry entry for NCT02576717 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,494 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RPC1063 is the first listed.
NCT02576717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02576717 about?
NCT02576717 is a clinical study titled "A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis". The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.
What is the current status of trial NCT02576717?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,494 participants. The study started on 2015-10-16. Estimated completion is 2023-01-05.
What interventions are being tested in trial NCT02576717?
The interventions under investigation include: RPC1063 (DRUG).
Who is sponsoring clinical trial NCT02576717?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.